Taysha Gene Therapies, Inc. TSHA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s accrued expenses?
- Taysha Gene Therapies, Inc. (TSHA) reported accrued expenses of $15.53M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s accrued expenses changed year-over-year?
- Taysha Gene Therapies, Inc.'s accrued expenses increased by 44.4% year-over-year, from $10.76M to $15.53M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s accrued expenses has grown at a 31.6% compound annual growth rate (CAGR), from $5.14M to $20.28M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.